Rafferty Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
Other funds holding RIGL
Rafferty Asset Management's RIGL Position: Q3 2026 in Review
Rafferty Asset Management increased its Rigel Pharmaceuticals (RIGL) stake by 14% in Q3 2026, buying an estimated $108K and bringing the position to 20,564 shares worth $990K. The position accounts for ﹤0.01% of the portfolio, ranked #775.
Rafferty Asset Management first reported a position in RIGL in Q1 2019 and has held it in 17 quarters since. The position peaked at $2.14M in Q1 2021. 170 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.
- Rafferty Asset Management held 20,564 shares of Rigel Pharmaceuticals worth $990K as of Q3 2026.
- Rafferty Asset Management bought 2,489 Rigel Pharmaceuticals shares in Q3 2026, an estimated $108K.
- Rigel Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #775 holding.
- Rafferty Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2019 and has held it in 17 quarters since.
- Rafferty Asset Management's Rigel Pharmaceuticals position peaked at $2.14M in Q1 2021.
- 170 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.